2023
Evolving systemic management of urothelial cancers
Tan W, Tan M, Alhalabi O, Campbell M, Kamat A, Gao J. Evolving systemic management of urothelial cancers. Current Opinion In Oncology 2023, 35: 186-199. PMID: 36966497, DOI: 10.1097/cco.0000000000000942.Peer-Reviewed Original ResearchConceptsPlatinum-based chemotherapyInvasive bladder cancerBladder cancerAntibody-drug conjugatesFibroblast growth factor receptorCheckpoint inhibitorsUrothelial carcinomaProgrammed cell death-ligand 1 inhibitorsLocalized muscle invasive bladder cancerImprove bladder cancer outcomesNonmuscle invasive bladder cancerTraditional platinum-based chemotherapyProgrammed cell death 1Management of urothelial carcinomaMuscle invasive bladder cancerImmune checkpoint inhibitorsCell death 1Third-line optionBladder cancer outcomesResponse to therapyGrowth factor receptorFood and Drug AdministrationDeath-1Second-lineSystemic treatment
2019
PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis
Tan W, Tan W, Inman B. PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis. Bladder Cancer 2019, 5: 211-223. PMID: 31867425, PMCID: PMC6919639, DOI: 10.3233/blc-190238.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsProgression-free survivalMetastatic urothelial carcinomaImmune checkpoint inhibitor therapyProgrammed death-ligand 1Response ratePooled Kaplan-Meier analysisBiomarker statusHigher overall response rateAnalyzed response ratesMetastatic urothelial cancerDeath-ligand 1Programmed death-1Platinum-based chemotherapyPD-L1/PD-1Kaplan-Meier analysisMeta-analysisOverall response rateProportional hazards survival analysisSystematic reviewComprehensive literature searchCheckpoint inhibitorsDeath-1PD-1Platinum therapy